Inclusion Criteria:  Patient with refractory or relapsing CD19 positive B-ALL or B-NHL defined as:  B-ALL refractory to treatment or in the second or subsequent relapse (hematological OR molecular), OR B-NHL refractory to treatment or in first relapse ineligible for autologous stem cell transplantation (ASCT) or in second to fourth relapse, OR B-ALL or B-NHL relapsing after autologous or allogeneic hematopoietic cell transplantation (HCT). CD19 expression on malignant cells confirmed by flow cytometry or by immunohistochemistry. Age ≥18 years and < 65 years. Patient able to understand and sign informed consent. Women of child-bearing potential: negative pregnancy test at enrolment (PSV) and at Visit 1.  General Exclusion Criteria:  Known hypersensitivity to any component of the Investigational Medicinal Product (IMP). Autologous or allogeneic HCT in 3 months prior to IMP administration. Vaccination with live virus vaccines in the 4 weeks before IMP administration and within 90 days after the IMP dose. Women: pregnancy or breast-feeding.  Subjects of fertile age, unless permanent sexual abstinence is their lifestyle choice:  female patients of childbearing potential not willing to use a highly effective method of contraception during the study, male patients whose sexual partner(s) are women of childbearing potential who are not willing to use a highly effective method of contraception during the study.  Exclusion criteria to Procurement of IMP manufacture starting material  Severe uncontrolled active infection. Positive test results for HIV1/2, Hepatitis B/C and lues.  Concurrent or recent prior therapies before apheresis:  Autologous or allogeneic hematopoietic cell transplantation within 12 weeks. Clofarabine, Fludarabine, Alemtuzumab within 8 weeks. Donor lymphocyte infusions within 4 weeks. Pegylated asparaginase within 4 weeks. Maintenance chemotherapy within 2 weeks. Long-acting Granulocyte Colony Stimulating Factor (G-CSF) within 2 weeks. Vincristine within 2 weeks. Intrathecal methotrexate within 1 week. Granulocyte Colony Stimulating Factor (G-CSF) within 5 days. Therapeutic dose of corticosteroids within 3 days. Short-acting cytostatics within 3 days  Exclusion criteria to IMP administration  Severe, uncontrolled active infections. Life expectancy < 6 weeks. Parenchymal central nervous system involvement Respiratory insufficiency (need for oxygen therapy). Significant liver impairment: bilirubin > 50 µmol/L, Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) > 4times normal upper limit. Acute kidney injury with serum creatinine > 180 µg/L, oliguria or dialysis. Heart failure with Ejection Fraction (EF) < 30% by echocardiography. Presence of active grade 3 - 4 acute GvHD